It was found that 3-fold intranasal administration of Arg-Pro-Gly-Pro peptide in a dose of 1 mg/kg body weight under conditions of experimental persistent hyperglycemia prevents the development of diabetes in experimental rats and produces normoglycemic, anticoagulant, fibrinolytic, and antiplatelet effects.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10517-012-1707-7DOI Listing

Publication Analysis

Top Keywords

anticoagulant fibrinolytic
8
fibrinolytic hypoglycemic
4
hypoglycemic effects
4
effects tetrapeptide
4
tetrapeptide arg-pro-gly-pro
4
arg-pro-gly-pro 3-fold
4
3-fold intranasal
4
intranasal administration
4
administration arg-pro-gly-pro
4
arg-pro-gly-pro peptide
4

Similar Publications

Hemorrhagic complications associated with regional anesthesia are extremely rare. The fifth edition of the American Society of Regional Anesthesia and Pain Medicine's Evidence-Based Guidelines on regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy reviews the published evidence since 2018 and provides guidance to help avoid this potentially catastrophic complication.The fifth edition of the American Society of Regional Anesthesia and Pain Medicine's Evidence-Based Guidelines on regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy uses similar methodology as previous editions but is reorganized and significantly condensed.

View Article and Find Full Text PDF

Pulmonary embolism (PE) and acute ischemic stroke (AIS) are serious conditions with high morbidity and mortality. In the USA, PE causes around 100,000 deaths annually, with higher incidence in males. AIS following PE occurs in 1-10% of cases and is a leading cause of death within 2 - 4 weeks post-stroke.

View Article and Find Full Text PDF

Acute massive pulmonary thromboembolism (PTE) is a potentially life-threatening condition requiring urgent management to decrease mortality. However, in the peripheral setting, managing the emergency can be challenging. We report a case of massive PTE presenting with cardiopulmonary arrest, successfully managed with advanced cardiac life support, early initiation of anticoagulants (heparin), and thrombolytics.

View Article and Find Full Text PDF

Factor XIa Inhibitor Reversal in Intracranial Hemorrhage: A Case Report.

Neurohospitalist

January 2025

Department of Neurology, Division of Neurocritical Care, University of North Carolina, Chapel Hill, NC, USA.

Background/objectives: There is currently no consensus regarding the optimal strategy for reversal of anticoagulation in life-threatening hemorrhage associated with factor XIa (FXIa) inhibitors.

Methods: For this clinical case report, informed consent was obtained from surrogate.

Results And Discussion: Here, we present the case of an 82-year-old female who sustained a large subdural hematoma after a fall.

View Article and Find Full Text PDF

Importance: Trials have not demonstrated superiority of alteplase or tenecteplase vs standard care in patients with mild stroke and have raised safety concerns. Prourokinase is an alternative fibrinolytic that may have a favorable safety profile, and the benefit-risk profile of prourokinase in mild stroke is unknown.

Objective: To investigate the efficacy and safety of prourokinase in mild ischemic stroke within 4.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!